Five Prime Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
An Activist Fund Has Been Buying This Biotech
Article By: Scott Matusow Friday, January 17, 2020 11:00 AM EDT
When a fund files a 13D, it indicates that it intends to be an activist investor. Activist investors often facilitate new business paths, partnerships, and acquisitions.
In this article: FPRX Also: BMY, MRK, ZLAB, XOMA
Read
Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals
Article By: ChinaBio® Today Saturday, December 23, 2017 5:37 PM EDT
Nanjing Legend Biotech and Janssen Biotech will form a global partnership with Legend for its CAR-T candidate and Crown Bioscience, a CRO with facilities in China, Taiwan, US and Europe, will be acquired for $400 million by JSR Corporation of Japan.
In this article: AVEO, CELG, FPRX, TRXC, BGNE, VTVT, ZLAB
Read
HH Small Cap Biotech Stocks Soar: How Long Will Rotation Last?
Article By: Rod Raynovich Thursday, October 5, 2017 9:06 PM EDT
Speculation in small cap biotech picks up, a boon for diligent traders. ETF buying is driving all small cap and microcap stocks higher.
In this article: AVEO, ZIOP, IJS, IWC, IWM, XBI, FPRX, RXDX, XNCR, CNCR, EDIT
Read
Magic Recipe Movers - The Trump Effect
Article By: Steve Alexander Sunday, November 13, 2016 10:45 PM EDT
It was a remarkable week for the markets in any case, with the S&P 500 rising 3.8%. It was quite the busy week, with the tail end of Q3 earnings calls and, of course, the historic and unexpected election of Donald Trump as the next president.
In this article: BBY, BKE, DLX, DVA, GBX, RGR, RHI, WU, AKRX, BIIB, MLHR, SWHC, UTHR, MNST, WSTC, FPRX, GMED, INSY, LBRDA, TGNA
Read
E Five Prime Therapeutics Enters Collaboration Agreement With Bristol-Myers
Article By: Terry Chrisomalis Thursday, October 15, 2015 9:36 AM EDT
Shares of Five Prime Therapeutics are up 62% after entering into a collaboration agreement with Bristol-Myers. Both companies entered into this agreement to collaborate on Five Prime's anti-body program for the treatment of cancer.
In this article: FPRX, BMY
Read
E Bluebird Bio Collaborates With Five Prime Therapeutics On Cell Therapy Drugs
Article By: Terry Chrisomalis Wednesday, May 27, 2015 6:54 PM EDT
After yesterday's collaboration announcement the stock resumes its climb, up 3.27% Wednesday.
In this article: BLUE, FPRX Also: CELG
Read
E The 0.01%
Article By: Vivian Lewis Saturday, October 25, 2014 2:28 PM EDT
I think we should vote 'nay' on some corporate proxies which provide excessive compensation for their brass.
In this article: AGU, CZZ, GSK, NOK, PT, VALE, MSFT, FBASF, ABGB, FPRX
Read
1 to 7 of 7 Posts